Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Gene Technology SureSeq CLL + CNV Panel

Oxford Gene Technology has launched the SureSeq CLL + CNV Panel for cancer research. The next-generation sequencing assay has been designed in collaboration with cancer experts to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia (CLL) progression.

The panel alleviates the burden of running multiple assays and delivers a comprehensive genomic profile for each CLL sample using a single workflow. It can identify loss of heterozygosity, copy number variation with a size range of a single exon to the whole gene, loss of chromosomal arms, and whole chromosome gains in trisomy 12. It comes with complimentary data analysis software.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.